{"id":10489,"date":"2026-01-07T17:55:21","date_gmt":"2026-01-07T16:55:21","guid":{"rendered":"https:\/\/www.ab-science.com\/?p=10489"},"modified":"2026-01-07T19:13:27","modified_gmt":"2026-01-07T18:13:27","slug":"ab-science-annonce-un-quatrieme-cas-consecutif-de-reponse-avec-la-combinaison-dab8939-et-du-venetoclax-dans-le-traitement-de-la-leucemie-myeloide-aigue-refractaire-ou-en-rechute-sur-la-base","status":"publish","type":"post","link":"https:\/\/www.ab-science.com\/fr\/ab-science-annonce-un-quatrieme-cas-consecutif-de-reponse-avec-la-combinaison-dab8939-et-du-venetoclax-dans-le-traitement-de-la-leucemie-myeloide-aigue-refractaire-ou-en-rechute-sur-la-base\/","title":{"rendered":"AB Science annonce un quatri\u00e8me cas cons\u00e9cutif de r\u00e9ponse avec la combinaison d\u2019AB8939 et du venetoclax dans le traitement de la leuc\u00e9mie my\u00e9lo\u00efde aigu\u00eb r\u00e9fractaire ou en rechute, sur la base des donn\u00e9es de phase 1"},"content":{"rendered":"<div class=\"wpb-content-wrapper\"><p>[vc_row][vc_column][vc_column_text css=\u00a0\u00bb\u00a0\u00bb]<\/p>\n<h3 class=\"Default\">07\/01\/2026 \u2013\u00a0AB Science fait aujourd\u2019hui le point sur l&rsquo;\u00e9tude de phase 1 de la mol\u00e9cule AB8939 et la quatri\u00e8me r\u00e9ponse cons\u00e9cutive avec la combinaison AB8939 + v\u00e9n\u00e9toclax chez des patients atteints de leuc\u00e9mie my\u00e9lo\u00efde aigu\u00eb<\/h3>\n<h3 class=\"Default\"><\/h3>\n<p>[\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column][vc_column_text css=\u00a0\u00bb\u00a0\u00bb]<iframe width=\"100%\" height=\"800\" src=\"https:\/\/www.ab-science.com\/themencode-pdf-viewer-sc\/?tnc_pvfw=ZmlsZT1odHRwczovL3d3dy5hYi1zY2llbmNlLmNvbS93cC1jb250ZW50L3VwbG9hZHMvMjAyNi8wMS9DUC1BQjg5MzktSkFOLTI2LVZGUi1WRi5wZGYmc2V0dGluZ3M9MTExMDExMTExMTExMTExMTEwMCZsYW5nPWVuLVVT#page=&zoom=100&pagemode=none\" title=\"\"><\/iframe>[\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column]<style type=\"text\/css\" data-type=\"the7_shortcodes-inline-css\">#default-btn-3daeea63a9caba98be1e66737e7fd730.ico-right-side > i {\n  margin-right: 0px;\n  margin-left: 8px;\n}\n#default-btn-3daeea63a9caba98be1e66737e7fd730 > i {\n  margin-right: 8px;\n}<\/style><div class=\"btn-align-center\"><a href=\"https:\/\/www.ab-science.com\/wp-content\/uploads\/2026\/01\/CP-AB8939-JAN-26-VFR-VF.pdf\" class=\"default-btn-shortcode dt-btn dt-btn-l link-hover-off  vc_custom_1749707699282\" target=\"_blank\" id=\"default-btn-3daeea63a9caba98be1e66737e7fd730\" rel=\"noopener\"><i class=\"dt-icon-the7-download\"><\/i><span>T\u00e9l\u00e9charger le PDF<\/span><\/a><\/div>[\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>[vc_row][vc_column][vc_column_text css=\u00a0\u00bb\u00a0\u00bb] 07\/01\/2026 \u2013\u00a0AB Science fait aujourd\u2019hui le point sur l&rsquo;\u00e9tude de phase 1 de la mol\u00e9cule AB8939 et la quatri\u00e8me r\u00e9ponse cons\u00e9cutive avec la combinaison AB8939 + v\u00e9n\u00e9toclax chez des patients atteints de leuc\u00e9mie my\u00e9lo\u00efde aigu\u00eb [\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column][vc_column_text css=\u00a0\u00bb\u00a0\u00bb][\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column][\/vc_column][\/vc_row]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[138],"tags":[],"class_list":["post-10489","post","type-post","status-publish","format-standard","hentry","category-2026-fr","category-138","description-off"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.4 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>AB Science annonce un quatri\u00e8me cas cons\u00e9cutif de r\u00e9ponse avec la combinaison d\u2019AB8939 et du venetoclax dans le traitement de la leuc\u00e9mie my\u00e9lo\u00efde aigu\u00eb r\u00e9fractaire ou en rechute, sur la base des donn\u00e9es de phase 1<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ab-science.com\/fr\/ab-science-annonce-un-quatrieme-cas-consecutif-de-reponse-avec-la-combinaison-dab8939-et-du-venetoclax-dans-le-traitement-de-la-leucemie-myeloide-aigue-refractaire-ou-en-rechute-sur-la-base\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AB Science annonce un quatri\u00e8me cas cons\u00e9cutif de r\u00e9ponse avec la combinaison d\u2019AB8939 et du venetoclax dans le traitement de la leuc\u00e9mie my\u00e9lo\u00efde aigu\u00eb r\u00e9fractaire ou en rechute, sur la base des donn\u00e9es de phase 1\" \/>\n<meta property=\"og:description\" content=\"[vc_row][vc_column][vc_column_text css=\u00a0\u00bb\u00a0\u00bb] 07\/01\/2026 \u2013\u00a0AB Science fait aujourd\u2019hui le point sur l&rsquo;\u00e9tude de phase 1 de la mol\u00e9cule AB8939 et la quatri\u00e8me r\u00e9ponse cons\u00e9cutive avec la combinaison AB8939 + v\u00e9n\u00e9toclax chez des patients atteints de leuc\u00e9mie my\u00e9lo\u00efde aigu\u00eb [\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column][vc_column_text css=\u00a0\u00bb\u00a0\u00bb][\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column][\/vc_column][\/vc_row]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.ab-science.com\/fr\/ab-science-annonce-un-quatrieme-cas-consecutif-de-reponse-avec-la-combinaison-dab8939-et-du-venetoclax-dans-le-traitement-de-la-leucemie-myeloide-aigue-refractaire-ou-en-rechute-sur-la-base\/\" \/>\n<meta property=\"og:site_name\" content=\"AB Science\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-07T16:55:21+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-07T18:13:27+00:00\" \/>\n<meta name=\"author\" content=\"Alexis BERNARD\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Alexis BERNARD\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/ab-science-annonce-un-quatrieme-cas-consecutif-de-reponse-avec-la-combinaison-dab8939-et-du-venetoclax-dans-le-traitement-de-la-leucemie-myeloide-aigue-refractaire-ou-en-rechute-sur-la-base\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/ab-science-annonce-un-quatrieme-cas-consecutif-de-reponse-avec-la-combinaison-dab8939-et-du-venetoclax-dans-le-traitement-de-la-leucemie-myeloide-aigue-refractaire-ou-en-rechute-sur-la-base\\\/\"},\"author\":{\"name\":\"Alexis BERNARD\",\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#\\\/schema\\\/person\\\/f22e8dbe9aaad0d416cbea66ecc4a755\"},\"headline\":\"AB Science annonce un quatri\u00e8me cas cons\u00e9cutif de r\u00e9ponse avec la combinaison d\u2019AB8939 et du venetoclax dans le traitement de la leuc\u00e9mie my\u00e9lo\u00efde aigu\u00eb r\u00e9fractaire ou en rechute, sur la base des donn\u00e9es de phase 1\",\"datePublished\":\"2026-01-07T16:55:21+00:00\",\"dateModified\":\"2026-01-07T18:13:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/ab-science-annonce-un-quatrieme-cas-consecutif-de-reponse-avec-la-combinaison-dab8939-et-du-venetoclax-dans-le-traitement-de-la-leucemie-myeloide-aigue-refractaire-ou-en-rechute-sur-la-base\\\/\"},\"wordCount\":190,\"publisher\":{\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#organization\"},\"articleSection\":[\"2026\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/ab-science-annonce-un-quatrieme-cas-consecutif-de-reponse-avec-la-combinaison-dab8939-et-du-venetoclax-dans-le-traitement-de-la-leucemie-myeloide-aigue-refractaire-ou-en-rechute-sur-la-base\\\/\",\"url\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/ab-science-annonce-un-quatrieme-cas-consecutif-de-reponse-avec-la-combinaison-dab8939-et-du-venetoclax-dans-le-traitement-de-la-leucemie-myeloide-aigue-refractaire-ou-en-rechute-sur-la-base\\\/\",\"name\":\"AB Science annonce un quatri\u00e8me cas cons\u00e9cutif de r\u00e9ponse avec la combinaison d\u2019AB8939 et du venetoclax dans le traitement de la leuc\u00e9mie my\u00e9lo\u00efde aigu\u00eb r\u00e9fractaire ou en rechute, sur la base des donn\u00e9es de phase 1\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#website\"},\"datePublished\":\"2026-01-07T16:55:21+00:00\",\"dateModified\":\"2026-01-07T18:13:27+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/ab-science-annonce-un-quatrieme-cas-consecutif-de-reponse-avec-la-combinaison-dab8939-et-du-venetoclax-dans-le-traitement-de-la-leucemie-myeloide-aigue-refractaire-ou-en-rechute-sur-la-base\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/ab-science-annonce-un-quatrieme-cas-consecutif-de-reponse-avec-la-combinaison-dab8939-et-du-venetoclax-dans-le-traitement-de-la-leucemie-myeloide-aigue-refractaire-ou-en-rechute-sur-la-base\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/ab-science-annonce-un-quatrieme-cas-consecutif-de-reponse-avec-la-combinaison-dab8939-et-du-venetoclax-dans-le-traitement-de-la-leucemie-myeloide-aigue-refractaire-ou-en-rechute-sur-la-base\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AB Science annonce un quatri\u00e8me cas cons\u00e9cutif de r\u00e9ponse avec la combinaison d\u2019AB8939 et du venetoclax dans le traitement de la leuc\u00e9mie my\u00e9lo\u00efde aigu\u00eb r\u00e9fractaire ou en rechute, sur la base des donn\u00e9es de phase 1\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/\",\"name\":\"AB Science\",\"description\":\"Masitinib and AB8939 \u2013 Two compounds with breakthrough mechanism of action\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#organization\",\"name\":\"AB Science\",\"url\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.ab-science.com\\\/wp-content\\\/uploads\\\/2020\\\/11\\\/logo_ab-science-wh120.png\",\"contentUrl\":\"https:\\\/\\\/www.ab-science.com\\\/wp-content\\\/uploads\\\/2020\\\/11\\\/logo_ab-science-wh120.png\",\"width\":120,\"height\":120,\"caption\":\"AB Science\"},\"image\":{\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/company\\\/ab-science\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#\\\/schema\\\/person\\\/f22e8dbe9aaad0d416cbea66ecc4a755\",\"name\":\"Alexis BERNARD\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/586e211c7d685fdd3428b70716f97574cf1b3149b055c1be5bdc5a7306e419bd?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/586e211c7d685fdd3428b70716f97574cf1b3149b055c1be5bdc5a7306e419bd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/586e211c7d685fdd3428b70716f97574cf1b3149b055c1be5bdc5a7306e419bd?s=96&d=mm&r=g\",\"caption\":\"Alexis BERNARD\"},\"url\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/author\\\/abernard\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"AB Science annonce un quatri\u00e8me cas cons\u00e9cutif de r\u00e9ponse avec la combinaison d\u2019AB8939 et du venetoclax dans le traitement de la leuc\u00e9mie my\u00e9lo\u00efde aigu\u00eb r\u00e9fractaire ou en rechute, sur la base des donn\u00e9es de phase 1","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ab-science.com\/fr\/ab-science-annonce-un-quatrieme-cas-consecutif-de-reponse-avec-la-combinaison-dab8939-et-du-venetoclax-dans-le-traitement-de-la-leucemie-myeloide-aigue-refractaire-ou-en-rechute-sur-la-base\/","og_locale":"fr_FR","og_type":"article","og_title":"AB Science annonce un quatri\u00e8me cas cons\u00e9cutif de r\u00e9ponse avec la combinaison d\u2019AB8939 et du venetoclax dans le traitement de la leuc\u00e9mie my\u00e9lo\u00efde aigu\u00eb r\u00e9fractaire ou en rechute, sur la base des donn\u00e9es de phase 1","og_description":"[vc_row][vc_column][vc_column_text css=\u00a0\u00bb\u00a0\u00bb] 07\/01\/2026 \u2013\u00a0AB Science fait aujourd\u2019hui le point sur l&rsquo;\u00e9tude de phase 1 de la mol\u00e9cule AB8939 et la quatri\u00e8me r\u00e9ponse cons\u00e9cutive avec la combinaison AB8939 + v\u00e9n\u00e9toclax chez des patients atteints de leuc\u00e9mie my\u00e9lo\u00efde aigu\u00eb [\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column][vc_column_text css=\u00a0\u00bb\u00a0\u00bb][\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column][\/vc_column][\/vc_row]","og_url":"https:\/\/www.ab-science.com\/fr\/ab-science-annonce-un-quatrieme-cas-consecutif-de-reponse-avec-la-combinaison-dab8939-et-du-venetoclax-dans-le-traitement-de-la-leucemie-myeloide-aigue-refractaire-ou-en-rechute-sur-la-base\/","og_site_name":"AB Science","article_published_time":"2026-01-07T16:55:21+00:00","article_modified_time":"2026-01-07T18:13:27+00:00","author":"Alexis BERNARD","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Alexis BERNARD","Dur\u00e9e de lecture estim\u00e9e":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.ab-science.com\/fr\/ab-science-annonce-un-quatrieme-cas-consecutif-de-reponse-avec-la-combinaison-dab8939-et-du-venetoclax-dans-le-traitement-de-la-leucemie-myeloide-aigue-refractaire-ou-en-rechute-sur-la-base\/#article","isPartOf":{"@id":"https:\/\/www.ab-science.com\/fr\/ab-science-annonce-un-quatrieme-cas-consecutif-de-reponse-avec-la-combinaison-dab8939-et-du-venetoclax-dans-le-traitement-de-la-leucemie-myeloide-aigue-refractaire-ou-en-rechute-sur-la-base\/"},"author":{"name":"Alexis BERNARD","@id":"https:\/\/www.ab-science.com\/fr\/#\/schema\/person\/f22e8dbe9aaad0d416cbea66ecc4a755"},"headline":"AB Science annonce un quatri\u00e8me cas cons\u00e9cutif de r\u00e9ponse avec la combinaison d\u2019AB8939 et du venetoclax dans le traitement de la leuc\u00e9mie my\u00e9lo\u00efde aigu\u00eb r\u00e9fractaire ou en rechute, sur la base des donn\u00e9es de phase 1","datePublished":"2026-01-07T16:55:21+00:00","dateModified":"2026-01-07T18:13:27+00:00","mainEntityOfPage":{"@id":"https:\/\/www.ab-science.com\/fr\/ab-science-annonce-un-quatrieme-cas-consecutif-de-reponse-avec-la-combinaison-dab8939-et-du-venetoclax-dans-le-traitement-de-la-leucemie-myeloide-aigue-refractaire-ou-en-rechute-sur-la-base\/"},"wordCount":190,"publisher":{"@id":"https:\/\/www.ab-science.com\/fr\/#organization"},"articleSection":["2026"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.ab-science.com\/fr\/ab-science-annonce-un-quatrieme-cas-consecutif-de-reponse-avec-la-combinaison-dab8939-et-du-venetoclax-dans-le-traitement-de-la-leucemie-myeloide-aigue-refractaire-ou-en-rechute-sur-la-base\/","url":"https:\/\/www.ab-science.com\/fr\/ab-science-annonce-un-quatrieme-cas-consecutif-de-reponse-avec-la-combinaison-dab8939-et-du-venetoclax-dans-le-traitement-de-la-leucemie-myeloide-aigue-refractaire-ou-en-rechute-sur-la-base\/","name":"AB Science annonce un quatri\u00e8me cas cons\u00e9cutif de r\u00e9ponse avec la combinaison d\u2019AB8939 et du venetoclax dans le traitement de la leuc\u00e9mie my\u00e9lo\u00efde aigu\u00eb r\u00e9fractaire ou en rechute, sur la base des donn\u00e9es de phase 1","isPartOf":{"@id":"https:\/\/www.ab-science.com\/fr\/#website"},"datePublished":"2026-01-07T16:55:21+00:00","dateModified":"2026-01-07T18:13:27+00:00","breadcrumb":{"@id":"https:\/\/www.ab-science.com\/fr\/ab-science-annonce-un-quatrieme-cas-consecutif-de-reponse-avec-la-combinaison-dab8939-et-du-venetoclax-dans-le-traitement-de-la-leucemie-myeloide-aigue-refractaire-ou-en-rechute-sur-la-base\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ab-science.com\/fr\/ab-science-annonce-un-quatrieme-cas-consecutif-de-reponse-avec-la-combinaison-dab8939-et-du-venetoclax-dans-le-traitement-de-la-leucemie-myeloide-aigue-refractaire-ou-en-rechute-sur-la-base\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.ab-science.com\/fr\/ab-science-annonce-un-quatrieme-cas-consecutif-de-reponse-avec-la-combinaison-dab8939-et-du-venetoclax-dans-le-traitement-de-la-leucemie-myeloide-aigue-refractaire-ou-en-rechute-sur-la-base\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.ab-science.com\/fr\/"},{"@type":"ListItem","position":2,"name":"AB Science annonce un quatri\u00e8me cas cons\u00e9cutif de r\u00e9ponse avec la combinaison d\u2019AB8939 et du venetoclax dans le traitement de la leuc\u00e9mie my\u00e9lo\u00efde aigu\u00eb r\u00e9fractaire ou en rechute, sur la base des donn\u00e9es de phase 1"}]},{"@type":"WebSite","@id":"https:\/\/www.ab-science.com\/fr\/#website","url":"https:\/\/www.ab-science.com\/fr\/","name":"AB Science","description":"Masitinib and AB8939 \u2013 Two compounds with breakthrough mechanism of action","publisher":{"@id":"https:\/\/www.ab-science.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ab-science.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.ab-science.com\/fr\/#organization","name":"AB Science","url":"https:\/\/www.ab-science.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.ab-science.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.ab-science.com\/wp-content\/uploads\/2020\/11\/logo_ab-science-wh120.png","contentUrl":"https:\/\/www.ab-science.com\/wp-content\/uploads\/2020\/11\/logo_ab-science-wh120.png","width":120,"height":120,"caption":"AB Science"},"image":{"@id":"https:\/\/www.ab-science.com\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/ab-science\/"]},{"@type":"Person","@id":"https:\/\/www.ab-science.com\/fr\/#\/schema\/person\/f22e8dbe9aaad0d416cbea66ecc4a755","name":"Alexis BERNARD","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/586e211c7d685fdd3428b70716f97574cf1b3149b055c1be5bdc5a7306e419bd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/586e211c7d685fdd3428b70716f97574cf1b3149b055c1be5bdc5a7306e419bd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/586e211c7d685fdd3428b70716f97574cf1b3149b055c1be5bdc5a7306e419bd?s=96&d=mm&r=g","caption":"Alexis BERNARD"},"url":"https:\/\/www.ab-science.com\/fr\/author\/abernard\/"}]}},"_links":{"self":[{"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/posts\/10489","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/comments?post=10489"}],"version-history":[{"count":0,"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/posts\/10489\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/media?parent=10489"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/categories?post=10489"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/tags?post=10489"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}